Acadian Asset Management’s Sutro Biopharma STRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $8.98M | Buy |
557,868
+184,029
| +49% | +$4.06M | 0.01% | 619 |
|
|
2026
Q2 | $12.4M | Buy |
373,839
+38,026
| +11% | +$1.19M | 0.01% | 525 |
|
|
2026
Q1 | $8.36M | Sell |
335,813
-2,140
| -0.6% | -$38.7K | 0.01% | 573 |
|
|
2025
Q4 | $3.91M | Sell |
337,953
-979
| -0.3% | -$9.29K | 0.01% | 720 |
|
|
2025
Q3 | $2.94M | Buy |
338,932
+34,708
| +11% | +$295K | 0.01% | 793 |
|
|
2025
Q2 | $2.17M | Sell |
304,224
-9,235
| -3% | -$75.5K | ﹤0.01% | 804 |
|
|
2025
Q1 | $2.04M | Buy |
313,459
+138,266
| +79% | +$2.18M | 0.01% | 751 |
|
|
2024
Q4 | $3.22M | Buy |
175,193
+14,206
| +9% | +$434K | 0.01% | 645 |
|
|
2024
Q3 | $5.57M | Buy |
160,987
+3,491
| +2% | +$137K | 0.02% | 481 |
|
|
2024
Q2 | $4.61M | Buy |
157,496
+37,071
| +31% | +$1.47M | 0.01% | 525 |
|
|
2024
Q1 | $6.8M | Buy |
120,425
+28,122
| +30% | +$1.24M | 0.02% | 393 |
|
|
2023
Q4 | $3.96M | Buy |
92,303
+14,916
| +19% | +$473K | 0.02% | 517 |
|
|
2023
Q3 | $2.68M | Buy |
77,387
+11,940
| +18% | +$520K | 0.01% | 604 |
|
|
2023
Q2 | $3.04M | Sell |
65,447
-3,277
| -5% | -$163K | 0.01% | 584 |
|
|
2023
Q1 | $3.17M | Buy |
68,724
+12,541
| +22% | +$796K | 0.01% | 581 |
|
|
2022
Q4 | $4.54M | Sell |
56,183
-6,997
| -11% | -$486K | 0.02% | 470 |
|
|
2022
Q3 | $3.5M | Sell |
63,180
-2,982
| -5% | -$176K | 0.02% | 499 |
|
|
2022
Q2 | $3.45M | Buy |
66,162
+42,346
| +178% | +$2.37M | 0.02% | 501 |
|
|
2022
Q1 | $1.96M | Buy |
23,816
+9,444
| +66% | +$899K | 0.01% | 669 |
|
|
2021
Q4 | $2.14M | Sell |
14,372
-3,857
| -21% | -$691K | 0.01% | 642 |
|
|
2021
Q3 | $3.44M | Sell |
18,229
-4,018
| -18% | -$764K | 0.01% | 540 |
|
|
2021
Q2 | $4.14M | Sell |
22,247
-1,492
| -6% | -$292K | 0.02% | 517 |
|
|
2021
Q1 | $5.4M | Buy |
23,739
+11,723
| +98% | +$2.78M | 0.02% | 457 |
|
|
2020
Q4 | $2.61M | Sell |
12,016
-675
| -5% | -$112K | 0.01% | 686 |
|
|
2020
Q3 | $1.28M | Buy |
12,691
+3,334
| +36% | +$315K | 0.01% | 813 |
|
|
2020
Q2 | $726K | Buy |
9,357
+462
| +5% | +$44.3K | ﹤0.01% | 1065 |
|
|
2020
Q1 | $908K | Buy |
8,895
+4,350
| +96% | +$457K | 0.01% | 823 |
|
|
2019
Q4 | $501K | Buy |
4,545
+1,474
| +48% | +$152K | ﹤0.01% | 1072 |
|
|
2019
Q3 | $279K | Buy |
3,071
+2,165
| +239% | +$219K | ﹤0.01% | 1236 |
|
|
2019
Q2 | $103K | Buy |
906
+844
| +1,361% | +$93K | ﹤0.01% | 1365 |
|
|
2019
Q1 | $7K | Buy |
+62
| New | +$6.45K | ﹤0.01% | 1889 |
|
Other funds holding STRO
Acadian Asset Management's STRO Position: Q3 2026 in Review
Acadian Asset Management increased its Sutro Biopharma (STRO) stake by 49% in Q3 2026, buying an estimated $4.06M and bringing the position to 557,868 shares worth $8.98M. The position accounts for 0.01% of the portfolio, ranked #619.
Acadian Asset Management first reported a position in STRO in Q1 2019 and has held it in 31 quarters since. The position peaked at $12.4M in Q2 2026. 59 funds tracked by Wall St. Rank hold STRO as of Q3 2026.
- Acadian Asset Management held 557,868 shares of Sutro Biopharma worth $8.98M as of Q3 2026.
- Acadian Asset Management bought 184,029 Sutro Biopharma shares in Q3 2026, an estimated $4.06M.
- Sutro Biopharma made up 0.01% of Acadian Asset Management's portfolio in Q3 2026, its #619 holding.
- Acadian Asset Management first reported a position in Sutro Biopharma in Q1 2019 and has held it in 31 quarters since.
- Acadian Asset Management's Sutro Biopharma position peaked at $12.4M in Q2 2026.
- 59 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2026.
Based on Acadian Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.